Mice modeling streptozotocin-induced type 1 diabetes treated with the C5aR1 antagonist PMX53, an orally active peptide, experienced significant reductions in inflammation, oxidative stress, and tissue damage, as indicated by reductions in albuminuria, urinary 8-isoprostane, and cytokines such as IL-18 [44]. The gene discussed is C5AR1; the disease is type 1 diabetes mellitus.